Navigation path

Pharmaceuticals - Community Register


List of nationally authorised medicinal products for human use

Targocid and associated names

Product name: Targocid and associated names
Also marketed in the EU under the name(s): Targosid, Teicomid, Teicoplanin Sanofi-Aventis
Active substance: teicoplanin
Indication: Targocid and associated names is indicated in adults and in children from birth for the parenteral treatment of the following infections:
• complicated skin and soft tissue infections,
• bone and joint infections,
• hospital acquired pneumonia,
• community acquired pneumonia,
• complicated urinary tract infections,
• infective endocarditis,
• peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),
• bacteraemia that occurs in association with any of the indications listed above.
Targocid and associated names is also indicated as an alternative oral treatment for Clostridium difficile infection associated diarrhoea and colitis.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.
Consideration should be given to official guidance on the appropriate use of antibacterial agents
Marketing Authorisation Holder: Not applicable

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/09/2013 Referral EMEA/H/A-30/1301 (2013)5930 of 12/09/2013